Repair Impact Fund

Scroll

Introduction

Novo Holdings is establishing the REPAIR Impact Fund to replenish the anti-infective pipeline and to combat antimicrobial resistance. The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.

Watch our new video about the investment process

Antimicrobial resistance – a major unmet need

Novel approaches are urgently needed to tackle the growing tide of antibiotic-resistant infections.

More than 700,000 people die each year from infections resistant to most or all antibiotics, and the number is increasing by the day. Such infections are projected to kill more people than cancer does by 2050, which would reduce global economic output by between 2% and 3.5% and severely cripple modern medical and surgical advances.

That makes anti-infective resistance one of the world’s most pressing medical problems. Although this growing issue is being generally recognized, the antibiotic pipeline remains thin.

Scientific Selection Board

A highly qualified Scientific Selection Board will support the selection of investments through an application process. The Board members are professionals with a mix of academic, clinical, industrial and scientific backgrounds.

Novo Holdings launches impact fund to combat antimicrobial resistance

Novo Holdings today announces the establishment of an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.

The fund is expected to invest USD 20 million to USD 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market.

Contact REPAIR Impact Fund

Novo Holdings A/S
Tuborg Havnevej 19 
2900 Hellerup 
Denmark 
repair@novo.dk

 Repair uses cookies to ensure that we give you the best experience on our website. Read more